—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Abivax SA (ABVX.PA) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for ABVX.PA, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
Who it is priced against Biotechnology · 8 names with week and year-to-date

Peer group

Biotechnology

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against ABVX.PA on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Abivax SA

ABVX.PA in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Abivax is a clinical-stage biotechnology company based in Paris that develops therapies aimed at calming the body's own immune response in chronic inflammatory disease. Its lead candidate, obefazimod, is in Phase 3 development for ulcerative colitis and in Phase 2b trials for Crohn's disease.
Where it sits in the stack
Abivax holds no seat in Rubin or Halo, so it does not sit inside the AI build-out stack; in Closelooknet's universe it is simply classed within the Healthcare sector as a biotechnology name.
Who it is priced against
Closelooknet's peer group places Abivax among other scored Healthcare names — argenx, Eli Lilly, Medpace, BeiGene, UCB, Fisher & Paykel Healthcare and Globus Medical — grouped by sector rather than by shared therapy area.
Why Closelooknet tracks it
Abivax carries a Closelooknet score, strongest on valuation and weakest on quality, but it has no index seat and no mentions in the diary's editions.
What the diary watches
The diary watches how the Phase 3 ulcerative colitis programme progresses, since a clinical-stage biotech's read hinges on trial results rather than steady earnings.

Abivax SA (ABVX.PA) trades on the PA exchange in France.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Abivax SA (ABVX.PA)?

Abivax SA trades as ABVX.PA on the PA exchange (France) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is ABVX.PA in a Closelooknet index?

Not currently — Abivax SA is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

Where does ABVX.PA trade against its moving averages?

Downtrend stack: Trades -17.8% vs the 50-day and -20.8% vs the 200-day average, 42.1% below the 52-week high and +33.1% off the 52-week low; a death cross printed 8 sessions ago. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Abivax SA compare with its peers?

Against its peer group (Biotechnology), Abivax SA (ABVX.PA) sits 42.1% below its 52-week high, 17.8% below its 50-day average; BB Biotech AG (BION.SW) is 12.9% below, BeiGene, Ltd. (ONC) is 5.8% below, Regeneron Pharmaceuticals Inc (REGN) is 15.5% below. Put any of them next to ABVX.PA in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

What does Abivax SA do?

Abivax is a clinical-stage biotechnology company based in Paris that develops therapies aimed at calming the body's own immune response in chronic inflammatory disease. Its lead candidate, obefazimod, is in Phase 3 development for ulcerative colitis and in Phase 2b trials for Crohn's disease. Closelooknet's peer group places Abivax among other scored Healthcare names — argenx, Eli Lilly, Medpace, BeiGene, UCB, Fisher & Paykel Healthcare and Globus Medical — grouped by sector rather than by shared therapy area.

Where does Abivax SA sit in the AI build-out?

Abivax holds no seat in Rubin or Halo, so it does not sit inside the AI build-out stack; in Closelooknet's universe it is simply classed within the Healthcare sector as a biotechnology name. Abivax carries a Closelooknet score, strongest on valuation and weakest on quality, but it has no index seat and no mentions in the diary's editions.

What does this page show?

A live price chart with SMA overlays and drawing tools for ABVX.PA, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.